Remove 2040 Remove Concentrates Remove Data
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. We recently announced a key milestone with the issuance of a method of use patent for ANEB-001, providing protection through 2040. Condensed Balance Sheet Data. . .